Abstract:Oncogenic rearrangements of the anaplastic lymphoma receptor tyrosine kinase (ALK gene) have recently been described in 3% to 5% of lung adenocarcinomas. Kinds of fusion partners of ALK have been reported in non-small-cell lung cancer (NSCLC), with echinoderm microtubule-associated protein-like 4 (EML4)-ALKbeing the most prevalent one. Several tyrosine kinase inhibitors have been approved for treating patients with advanced-stage ALK-positive, NSCLC by Food and Drugs Administration (FDA).Comprehensive genomic profiling performed by means of next-generation sequencing assay demonstrated a novel myosin phosphatase-Rho-interacting protein gene (MPRIP)-ALK fusion in our case, in which a translocation involving chromosomes 2 and 9 has taken place. The rearrangement was verified by reverse transcription reverse transcription polymerase chain reaction (RT-PCR) and Sanger sequencing. ALK immunohistochemistry demonstrated strong staining in patient’s tumor sample as extracted from formalin-fixed paraffin-embedded (FFPE) sections.We expressed MPRIP-ALK cDNA construct in non-cancer cell line Ba/F3 which showed IL-3-independent growth compared the growth stop of cells carrying empty vector, moreover, hyper-activation of the protein ALK, ERK, AKT were detected in Ba/F3 cells with MPRIP-ALK over-expressed. Furthermore, the colonies and activations of ALK downstream signaling pathways could be inhibited by crizotinib. The patient received standard chemotherapy on the first-line. She experienced progressive disease after 7 months, and commenced on crizotinib (250mg, twice per day) from March 2018. The patient showed significant improvement in cough, dorsalgia, and polypnea within one week. Partial response was gained after one month treatment and confirmed at the third month. She still remains on the crizotinib treatment without disease relapse up to now. In this study, we report a novel ALK rearrangement in a patient with NSCLC by RNA-seq. Our in vivo and in vitro studies have shown that the novel MPRIP-ALK fusion is a driver gene and can be targetable by crizotinib.Citation Format: Wenfeng Fang, Jiadi Gan, Feng Lu, Yangyang Deng, Liang Chen, Yunpeng Yang, Li Zhang. MPRIP-ALK,a novel ALK rearrangement that responds to ALK inhibitor in non-small-cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3460.

STRN-ALK, A Novel In-Frame Fusion with Response to Alectinib.

STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review

ALK: a tyrosine kinase target for cancer therapy

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report

PLEKHH2-ALK: A Novel In-frame Fusion with Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy

Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy

Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report

Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib

Primary Resistance to Alectinib in a Patient with STRN‐ALK‐positive Non‐small Cell Lung Cancer: A Case Report

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

A Novel SLC8A1-ALK Fusion in Lung Adenocarcinoma Confers Sensitivity to Alectinib: A Case Report

Identification of a novel RSRC1-ALK (R6: A20) fusion using next-generation sequencing technique

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review

Genomic Characterization and Outcome Evaluation of Kinome Fusions in a Large Non-Small Cell Lung Cancer Population.

Novel NLRC4‐ALK and EML4‐ALK Double Fusion Mutations in a Lung Adenocarcinoma Patient: A Case Report

Abstract 3460:Mprip-Alk,a Novel ALK Rearrangement That Responds to ALK Inhibitor in Non-Small-cell Lung Cancer

Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases

A Novel Intergenic Gene Between SLC8A1 and PKDCC-ALK Fusion Responds to ALK TKI WX-0593 in Lung Adenocarcinoma: A Case Report